Abstract
Paclitaxel (Taxol), a promoter of microtubule polymerization and a radiosensitizing agent, is one of the more active anticancer drugs in the current treatment of solid tumors. In this study, we show that paclitaxel possesses an antiangiogenic property associated with a down-regulation of vascular endothelial growth factor (VEGF) in a highly-vascularized transgenic murine breast cancer (Met-1). Paclitaxel, at non-cytotoxic doses of 0, 3 and 6 mg/kg/day, was administered intraperitoneally for 5 days to nude mice bearing the Met-1 breast tumor. Extent of intratumoral angiogenesis, as indicated by microvessel tortuosity and microvessel density, was significantly reduced by paclitaxel in a dose-dependent manner. Paclitaxel also suppressed expression of VEGF in the Met-1 cells transplanted in nude mice or maintained in cell culture. These results indicate that antiangiogenesis associated with a down-regulation of VEGF is an additional mode of action of paclitaxel.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 31-36 |
| Number of pages | 6 |
| Journal | Cancer Biotherapy and Radiopharmaceuticals |
| Volume | 14 |
| Issue number | 1 |
| State | Published - 1999 |
Fingerprint
Keywords
- Anti-angiogenesis
- Breast cancer
- Paclitaxel
- VEGF
ASJC Scopus subject areas
- Cancer Research
- Pharmacology
- Oncology
Cite this
Paclitaxel (Taxol) : An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. / Lau, Derick H; Xue, Ling; Young, Lawrence J.; Burke, Patricia A.; Cheung, Anthony T.
In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 14, No. 1, 1999, p. 31-36.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Paclitaxel (Taxol)
T2 - An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer
AU - Lau, Derick H
AU - Xue, Ling
AU - Young, Lawrence J.
AU - Burke, Patricia A.
AU - Cheung, Anthony T.
PY - 1999
Y1 - 1999
N2 - Paclitaxel (Taxol), a promoter of microtubule polymerization and a radiosensitizing agent, is one of the more active anticancer drugs in the current treatment of solid tumors. In this study, we show that paclitaxel possesses an antiangiogenic property associated with a down-regulation of vascular endothelial growth factor (VEGF) in a highly-vascularized transgenic murine breast cancer (Met-1). Paclitaxel, at non-cytotoxic doses of 0, 3 and 6 mg/kg/day, was administered intraperitoneally for 5 days to nude mice bearing the Met-1 breast tumor. Extent of intratumoral angiogenesis, as indicated by microvessel tortuosity and microvessel density, was significantly reduced by paclitaxel in a dose-dependent manner. Paclitaxel also suppressed expression of VEGF in the Met-1 cells transplanted in nude mice or maintained in cell culture. These results indicate that antiangiogenesis associated with a down-regulation of VEGF is an additional mode of action of paclitaxel.
AB - Paclitaxel (Taxol), a promoter of microtubule polymerization and a radiosensitizing agent, is one of the more active anticancer drugs in the current treatment of solid tumors. In this study, we show that paclitaxel possesses an antiangiogenic property associated with a down-regulation of vascular endothelial growth factor (VEGF) in a highly-vascularized transgenic murine breast cancer (Met-1). Paclitaxel, at non-cytotoxic doses of 0, 3 and 6 mg/kg/day, was administered intraperitoneally for 5 days to nude mice bearing the Met-1 breast tumor. Extent of intratumoral angiogenesis, as indicated by microvessel tortuosity and microvessel density, was significantly reduced by paclitaxel in a dose-dependent manner. Paclitaxel also suppressed expression of VEGF in the Met-1 cells transplanted in nude mice or maintained in cell culture. These results indicate that antiangiogenesis associated with a down-regulation of VEGF is an additional mode of action of paclitaxel.
KW - Anti-angiogenesis
KW - Breast cancer
KW - Paclitaxel
KW - VEGF
UR - http://www.scopus.com/inward/record.url?scp=0032930199&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032930199&partnerID=8YFLogxK
M3 - Article
C2 - 10850285
AN - SCOPUS:0032930199
VL - 14
SP - 31
EP - 36
JO - Cancer Biotherapy and Radiopharmaceuticals
JF - Cancer Biotherapy and Radiopharmaceuticals
SN - 1084-9785
IS - 1
ER -